Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals
https://www.zacks.com/stock/news/2206363/pharma-stock-roundup-lly-s-new-digital-pharmacy-nvo-abbv-s-fresh-r-d-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2206363
Jan 05, 2024 - Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.
0
Here's Why Sanofi (SNY) is a Strong Value Stock
https://www.zacks.com/stock/news/2204141/here-s-why-sanofi-sny-is-a-strong-value-stock?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2204141
Jan 01, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program
https://www.zacks.com/stock/news/2201634/sanofi-sny-discontinues-tusamitamab-ravtansine-cancer-program?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201634
Dec 22, 2023 - Sanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint.
0
Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate
https://www.zacks.com/stock/news/2201507/pharma-stock-roundup-fda-nod-to-azn-s-eplontersen-crl-to-mrk-s-cough-candidate?cid=CS-ZC-FT-analyst_blog|stock_roundup-2201507
Dec 22, 2023 - FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.
0
Top Analyst Reports for Alphabet, Comcast & NextEra Energy
https://www.zacks.com/commentary/2201007/top-analyst-reports-for-alphabet-comcast-nextera-energy?cid=CS-ZC-FT-research_daily-2201007
Dec 21, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Comcast Corp. (CMCSA) and NextEra Energy, Inc. (NEE).
0
3 Stocks to Buy Before 2024 That Can Set You Up For Life
https://www.fool.com/investing/2023/12/14/3-stocks-to-buy-before-2024-that-can-set-you-up/?source=iedfolrf0000001
Dec 14, 2023 - These stocks are still relatively cheap, but don't expect them to stay that way for long.
0
AstraZeneca (AZN) to Acquire Vaccine Maker Icosavax for $1.1B
https://www.zacks.com/stock/news/2196741/astrazeneca-azn-to-acquire-vaccine-maker-icosavax-for-1-1b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196741
Dec 12, 2023 - AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Icosavax, for a total deal value of up to $1.1 billion.
0
Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects
https://www.zacks.com/stock/news/2196713/sanofi-sny-terminates-pompe-disease-deal-as-ftc-objects?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196713
Dec 12, 2023 - Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.
0
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
https://www.zacks.com/stock/news/2195113/sanofi-sny-posts-upbeat-long-term-outlook-enhances-r-d-focus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195113
Dec 07, 2023 - Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
0